Jefferies raises Merck stock price target on Winrevair trial data

Jefferies raised Merck (MRK) price target to $138 from $132 and kept a Buy after full Phase 2 CADENCE results; Jefferies models $1.3bn risk-adjusted peak sales for Winrevair with a 50% probability of success. CADENCE showed a -1.02 vs placebo pulmonary vascular resistance shift for 0.3mg/kg and -0.75 for 0.7mg/kg (lower than PAH Phase 3 ~-2.93), with six-minute walk distance +20.3m for 0.3mg/kg (not formally tested) and +5.8m for 0.7mg/kg (not significant). Separately, Phase 3 CORALreef AddOn data for oral PCSK9 inhibitor enlicitide showed a 64.6% LDL-C reduction at eight weeks, and Merck’s bid for Terns values the company at $53/sh, prompting mixed analyst reactions (Mizuho downgrade on Terns, Guggenheim reiterates Buy on Merck).

Analysis

Merck is sitting on asymmetric optionality: an oral PCSK9 candidate plus incremental hematology assets from the Terns bid create multiple, partially uncorrelated value levers that can re-rate the stock over 6–24 months if either commercialization or M&A synergy paths accelerate. The market currently prices much of the near-term CADENCE ambiguity into the share price but appears to underweight upside from a successful oral PCSK9 launch, which would not only take share from injectables but also change payer negotiating dynamics and channel economics (lower cold‑chain/device costs) within ~2–5 years.

Second-order winners include CMO/SMO small‑molecule manufacturers and payers who benefit from simpler administration; losers would be injectable-device vendors and incumbents that depend on durable, high-priced injectables for margin. The Terns deal reduces binary takeover risk for MRK but increases execution risk (integration, milestone funding) — expect analyst EPS revisions clustered around the close and the next 12 months of pipeline readouts.

Near-term catalysts: merger vote/timelines, next PCSK9 positioning updates, and any scheduled Phase 3/registration decisions over the next 6–18 months. Tail risks are classic biotech binary outcomes — Phase 3 failure, FDA surprise safety issues, or a bid failure for Terns — any of which could subtract 10–25% from the current implied value in <90 days. Contrarian stance: consensus is too centered on CADENCE noise; the call option value of an oral PCSK9 plus accretive hematology assets likely justifies a modest overweight now rather than waiting for binary de-risking events to reprice upside away.

Key Decisions for Investors

• Overweight MRK via a defined‑risk call spread: buy a 9–12 month ATM call and sell a 30% OTM call (size 2–5% NAV). Aim to capture a 20–30% re‑rating if pipeline/M&A catalysts come in; max loss limited to premium paid. Enter on any post‑catalyst dip >3% to improve R/R.
• Merger arbitrage on TERN: initiate a long TERN position sized 2–3% NAV if the stock trades ≥4% below the $53 offer (implied spread >4%) with expected close in 3–6 months. Hedge tail risk by buying cheap 3–6 month puts (protects against deal failure); target annualized carry 15–40% depending on spread/timeline.
• Paired sector trade for 12–36 months: long MRK / short AMGN (or REGN) equal notional to express upside from oral PCSK9 and hematology M&A while hedging class risk. Target 15–25% gross return if MRK captures share; downside if MRK pipeline fails, so keep position size modest (3–5% NAV).
• Buy a tactical hedge: purchase 3–6 month MRK puts ~5–7% OTM sized to cover 1–2% NAV ahead of key readouts/Vote periods. Cost is the insurance premium but caps 1–2% portfolio tail exposure if a bad binary outcome hits within 90 days.